NLP · 3-line summary

AI Articles & Report Summaries

Expert articles and reports as a 3-line summary + takeaway

All Industrials Big Tech Macro Financials Consumer Energy Bio Semis Battery

BioLive Wire · AI-collected

Arcus Biosciences Shares Fall 6% After Unveiling Casdatifan Kidney-Cancer Trial Data

Arcus Biosciences presented new clinical data at a New York investor event for its HIF-2alpha inhibitor casdatifan in clear cell renal cell carcinoma from its ARC-20 platform study, evaluating first-line combination therapy, second-line treatment, and later-line monotherapy; shares fell 6% following the presentation.
In first-line therapy (casdatifan plus zimberelimab, 30 patients, median follow-up 11.5 months), 6- and 12-month progression-free survival rates were 86% and 69%, with a confirmed objective response rate of 50%; in second-line therapy (casdatifan plus cabozantinib, 43 patients), median progression-free survival was 14.5 months. In the pooled previously treated monotherapy cohort, median overall survival was 35 months, median progression-free survival 13 months, and confirmed objective response rate 36%, with no unexpected safety signals observed as of the September 4, 2026 data cutoff.
The company said first-line progression-free survival exceeded benchmarks for pembrolizumab monotherapy and ipilimumab-plus-nivolumab combination therapy, and second-line results exceeded the cabozantinib-monotherapy benchmark; Phase 3 PEAK-20 (casdatifan plus ipilimumab/nivolumab) is set to begin later this year, and Phase 3 PEAK-1 (casdatifan plus cabozantinib, second-line) is ongoing.

Published 4d agoSource: Investing.com ↗

BioLive Wire · AI-collected

Alvotech Shares Jump Premarket After FDA Approves New Manufacturing Process for Simlandi

Biosimilar maker Alvotech said the FDA approved a new manufacturing process, "Process 2.0," for producing the adalimumab (Humira biosimilar Simlandi) drug substance at its DSM2 facility in Reykjavik, Iceland; the company said the process more than doubles drug-substance output per batch without changing upstream production scale, and demonstrated comparability to the existing approved process with quality, safety, and efficacy maintained.
Alvotech COO Joseph McClellan said "the new process allows us to manufacture the same quantity of drug substance in fewer batches," freeing up capacity that can be redirected to other products in the company's portfolio, which includes five approved biosimilars sold in multiple countries: Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva.
Shares rose more than 6% in premarket trading Tuesday; the approval follows a recent FDA capacity approval and gives the company more flexibility to respond to demand increases.

Published 4d agoSource: Investing.com ↗

BioLive Wire · AI-collected

AstraZeneca Partners With Oracle on AI-Driven Clinical Research

AstraZeneca and Oracle announced a partnership to use AI to improve clinical research processes, drawing on Oracle's AI, cloud computing, and data-management systems; the collaboration focuses on applying AI to connect scientific research with clinical workflows rather than discovering new drug targets.
Planned applications include clinical-trial patient recruitment, earlier disease diagnosis, and drug-safety monitoring; the first program will address hypertension treatment and clinical research in Abu Dhabi alongside healthcare group M42, before expanding to additional projects across the US, Middle East, and Europe.
The partnership is expected to span AstraZeneca's core therapeutic areas, including oncology, cardiovascular disease, kidney and metabolic disease, respiratory and immunology, and rare diseases; neither company disclosed financial terms or a contract duration.

Published 4d agoSource: Investing.com ↗

BioLive Wire · AI-collected

California Settles 23andMe Data Breach Claims for $6 Million

California Attorney General Rob Bonta's office said Monday the state will receive $6 million from bankrupt 23andMe to resolve state legal claims tied to the company's 2023 data breach, which exposed the genetic and other personal information of 6.9 million customers, including more than 855,000 California residents; the state alleged violations of California's Genetic Information Privacy Act, arguing consumers had not explicitly consented to the asset sale.
23andMe filed for bankruptcy in March 2025 amid falling demand and legal fallout from the breach, selling its business through auction for $305 million to TTAM Research Institute, a nonprofit controlled by co-founder Anne Wojcicki; separately, 23andMe agreed in bankruptcy proceedings to pay $46.75 million to victims of the 2023 breach.
The bankruptcy court had rejected California's objection to the sale and barred the state from suing the successor company; after losing an appeal in federal district court, California agreed to drop further appeals as part of the settlement. Bonta emphasized that consumers can still delete their genetic information.

Published 5d agoSource: Reuters ↗

BioLive Wire · AI-collected

Evaxion Stock Surges on 3-Year Melanoma Vaccine Trial Data

Evaxion said all patients in a Phase 2 trial of its AI-designed personalized cancer vaccine EVX-01 for advanced melanoma maintained the clinical response seen at year two through the three-year follow-up mark, with no tumor progression observed; patients received EVX-01 as monotherapy in year three.
At the two-year mark (presented at ESMO 2025), the trial showed a 75% objective response rate, 25% complete response, 92% durability of response, and no relapses after combining EVX-01 with Merck's Keytruda for the first two years; 6 of 12 responders entered a one-year extension on monotherapy. Additional two-year data showed 54% of patients had deepening responses after treatment, tumor shrinkage in 15 of 16 enrolled patients, and vaccine-specific T-cell responses against 86% of targeted neoantigens.
Evaxion shares (EVAX) rose 21.6% Monday; the company plans to present the data at the ESMO Congress 2026 in Madrid (October 23-27) followed by a webinar on October 29.

Published 5d agoSource: Investing.com ↗

BioLive Wire · AI-collected

Metis TechBio Inks Up to $1.1 Billion Deal With Eli Lilly for Drug Delivery Tech

Hong Kong-listed Metis TechBio signed a collaboration agreement with Eli Lilly for research and development of tissue-specific drug delivery technologies, with a total deal value of up to $1.1 billion; the article did not specify upfront payment, milestone terms, or payment structure, only the aggregate cap.
No specific timeline or further details on the collaboration's duration were given in the article.

Published 5d agoSource: Investing.com ↗

BioLive Wire · AI-collected

Medicalgorithmics Shares Rally on $67 Million Takeover Letter of Intent

Polish healthcare company Medicalgorithmics (MDG) said a Nasdaq-listed US healthcare company signed a letter of intent to acquire 100% of its shares for total consideration of at least $67 million, to be paid primarily in the acquirer's common stock.
The acquirer plans to raise at least 10 million euros in non-debt equity financing before or at the signing of a definitive agreement; the current stage is the letter of intent, with a final agreement still to follow and no timeline or closing conditions specified.
Medicalgorithmics shares jumped 7.4% following the announcement.

Published 5d agoSource: Investing.com ↗

BioLive Wire · AI-collected

GSK's Ris-Rez Shows 61% Response Rate in Small Cell Lung Cancer Trial

GSK said Monday its experimental lung-cancer drug risvutatug rezetecan (Ris-Rez), licensed from China's Hansoh Pharma, showed a confirmed response in 11 of 18 evaluable patients (about 61%) at the high 8 mg/kg dose in an early global trial of extensive-stage small cell lung cancer patients who had relapsed after prior treatment, versus 7 of 22 (32%) at the lower 6 mg/kg dose; Grade 3-or-higher adverse events were more frequent at the high dose (42%) than the low dose (15%).
The trial enrolled 50 patients, most previously treated with two prior therapies, with roughly 100.5 days of follow-up and enrollment still ongoing; standard-of-care median overall survival for this setting is about 12-13 months, though the article did not give a direct standard-of-care response-rate comparison. GSK said longer follow-up is needed to assess durability of response, and results will be presented at the ESMO Congress 2026 in Madrid.
GSK will advance the 8 mg/kg dose into its global late-stage trial EMBOLD SCLC-301, a decision informed by this data and by Hansoh's pivotal China trial, which GSK said showed a statistically significant overall-survival improvement; GSK holds exclusive global rights to the drug excluding mainland China, Hong Kong, Macau, and Taiwan, and more than 1,000 patients have received it across trials including a late-stage study in hormone-resistant prostate cancer.

Published 5d agoSource: Investing.com ↗

BioLive Wire · AI-collected

Novavax Shareholder Shah Capital to Step Back From Activist Role

Shah Capital said Friday it no longer seeks to influence control of Novavax, as the firm restructures its investment organization into a family office; Shah Capital filed to voluntarily withdraw its SEC registration as an investment adviser, with the newly formed Himanshu Shah Family Office LLC to manage investments going forward.
Shah Capital's beneficial holding stands at 10.54 million shares (about 6.39%), while founder, CEO/CIO Himanshu Shah's personal beneficial holding is 10.66 million shares (about 6.46%); per LSEG data, Shah is Novavax's second-largest shareholder.
A recent filing showed Shah Capital Fund LLC sold 2.8 million shares at an average price of about $11.35 on October 5. The article did not provide further detail on the reason for the activist withdrawal beyond the shift to a family office.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

Novartis Ends Mid-Stage Trial for Fabhalta in Lupus Nephritis

Novartis halted a mid-stage trial testing Fabhalta in patients with lupus nephritis, according to the US federal clinical-trials registry, updated October 15. The company cited 'strategic considerations' for the decision, made after completing Part 1; the registry listing did not provide further explanation, and did not indicate whether safety or efficacy concerns influenced the decision.
The trial was evaluating whether the oral drug, used alongside standard treatment, was safe and effective for lupus nephritis — severe kidney inflammation caused by the autoimmune disease lupus.
Fabhalta was first approved by the FDA in 2023 for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, and has since been approved for two kidney diseases, IgA nephropathy and C3 glomerulopathy; the article did not address whether this trial halt affects those approved indications.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

Eli Lilly's Weight-Loss Pill Foundayo Wins EU Drug Regulator's Backing

Eli Lilly's oral weight-loss pill Foundayo (orforglipron) received a recommendation for approval from an EMA committee, for use in adult weight management and type 2 diabetes treatment; final marketing authorization rests with the European Commission. It becomes the second oral weight-loss drug to win EU backing, after Novo Nordisk's oral Wegovy.
Bernstein analyst Courtney Breen expects a European launch for the obesity indication around year-end, while the diabetes indication's timing may vary by country based on individual reimbursement decisions. Foundayo launched in the US in April and the UK in August, posting $98 million in Q2 sales; oral Wegovy, which won EU approval in July and is also sold in the US, UK, and UAE, posted DKK 322 million (about $48.45 million) in the same period.
Context: Foundayo's US rollout has been slower than Wegovy's, which entered the market first, though Foundayo can be taken at any time of day without food or water restrictions — a differentiator whose effect on adoption remains unclear. Lilly has filed for approval in more than 40 countries; Lilly and Novo are both competing to expand access to oral obesity drugs, in a market expected to exceed $100 billion by 2030, with oral drugs seen as potentially broadening the obesity-treatment market by attracting patients who are averse to injections.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

City Therapeutics Allocated No Shares to Half of IPO Orders, Report Says

City Therapeutics allocated no shares to half of investor orders in its IPO, Bloomberg reported (via Investing.com) October 16. Demand from mutual funds and healthcare-specialist investors for the upsized offering reached several times the available share count; the top 5 investors received 65% of the allocation and the top 10 received about 90%, with company management reported to have been deeply involved in the allocation process. The article did not give a specific reason for excluding half of the orders beyond demand far exceeding supply.
As previously reported, the IPO priced 11,111,111 shares at $18.00 each, expected to raise about $200 million before fees, with underwriters holding a 30-day option for up to 1,666,666 additional shares; underwriters were Goldman Sachs, Jefferies, Stifel, and Oppenheimer. Shares were set to begin trading on the Nasdaq Global Market under ticker CTY.

Published Oct 16Source: Bloomberg ↗

BioLive Wire · AI-collected

Alector Stock Surges 13% on Premium-Priced Equity Offering

Alector shares jumped about 13% in Friday premarket trading after the company priced a registered direct offering of 36.6 million common shares at $2.05 per share — about a 7.3% premium to its October 15 closing price; the deal is expected to raise approximately $75.03 million before fees, with closing expected around October 19 subject to customary conditions.
New and existing investors are participating, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. Morgan Stanley and BTIG are acting as joint lead underwriters.
Alector, headquartered in South San Francisco, develops therapies aimed at slowing progression of neurodegenerative diseases. Proceeds are earmarked for R&D, manufacturing of drug candidates, working capital, capital expenditures, and general corporate purposes, as well as potential acquisitions or strategic transactions involving complementary products, technologies, or businesses. The article attributed the share-price jump to the above-prior-close offering pricing but did not provide further analysis of the market reaction.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

Omeros Shares Slide Following European Regulatory Setback for Narsoplimab

The European Medicines Agency's CHMP maintained a negative opinion on narsoplimab after re-examination, declining to approve it for transplant-associated thrombotic microangiopathy (TA-TMA) following stem-cell transplant — reaffirming its initial negative stance from June 2026. An 8-member expert group convened by CHMP had recommended that individual patient-level data be reviewed by outside experts, but per the report, CHMP did not provide that data to the expert group before its decision; Omeros had submitted substantial patient data in August.
Omeros shares fell about 4% in Friday morning trading. In response, Omeros told CHMP it will end its European compassionate-use program for the drug, citing surging US demand; European patients currently on the program will receive enough supply to complete their treatment course. The company plans to start trials for acute respiratory distress syndrome (ARDS) and prevention of high-risk pediatric TA-TMA later this year.
Narsoplimab targets MASP-2, an enzyme in the lectin pathway of the complement system. The FDA approved it in December 2025 under the brand name Yartemlea, the first FDA-approved treatment for TA-TMA in patients age 2 and older — a contrast the article drew with the EU rejection. The article noted it is the only marketed systemic complement inhibitor without a boxed warning, REMS, or specific vaccination requirements, and cited rising US demand as the direct reason for ending the European program.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

City Therapeutics Prices IPO at $18 Per Share, Raising $200 Million

City Therapeutics (ticker: CTY), a clinical-stage biotech developing RNA-interference therapies, priced its IPO at $18 per share for 11,111,111 shares, raising about $200 million before fees; the offering is entirely newly issued shares, with underwriters granted a 30-day option to purchase up to 1,666,666 additional shares. The stock lists on the Nasdaq Global Market, with the SEC registration statement effective October 15, trading starting October 16, and closing expected October 19.
Underwriters include Goldman Sachs & Co. LLC, Jefferies, Stifel, and Oppenheimer & Co. Key pipeline programs cited: CITY-FXI for thromboembolic disorders, CITY-RBP4 for Stargardt disease and other retinal disorders, and CITY-TFR2 for anemia related to chronic disease.
The article did not specify planned use of proceeds.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

Catalio Capital Seeks $500 Million for AI-Healthcare Startups, Bloomberg Reports

Catalio Capital is seeking $500 million for its second AI-healthcare-startup fund, named Nexus V, moved up from a previously planned 2027 launch, according to an investor letter cited by Bloomberg. Five existing portfolio companies will carry over into the new fund, including Doctronic (AI personalized healthcare) and Basecamp Research (AI-designed therapeutics).
Catalio's prior fund closed in July 2025 at over $400 million, with about 40% of its portfolio AI-related. The firm has sold three portfolio companies this year for a combined deal value exceeding $8 billion, and has taken seven companies public, including this week's $150 million Iambic Therapeutics IPO and June's $745 million Parabilis Medicines IPO.
KKR took a minority stake in Catalio in 2023, and KKR co-founder Henry Kravis chairs Catalio's board.

Published Oct 15Source: Investing.com ↗

BioLive Wire · AI-collected

Pennsylvania Secures $4 Billion in Investments, Governor Says

Pennsylvania Governor Josh Shapiro announced over $4 billion in life-sciences and private-sector investment commitments secured over the past week, per Investing.com. Merck committed $2.9 billion to expand its Montgomery County site through the end of 2030, including $550 million for a robotics- and AI-enabled drug R&D and manufacturing facility; GSK committed more than $800 million to expand its Upper Merion site for biopharmaceutical manufacturing and research, creating more than 300 jobs over five years.
The state also committed $371.5 million toward port infrastructure to expand container and vehicle handling capacity, expected to draw an additional $200 million in private investment and $266 million in federal support. The combined investments are expected to create more than 6,300 jobs for Pennsylvania residents.

Published Oct 15Source: Investing.com ↗

BioLive Wire · AI-collected

Iambic Therapeutics Prices IPO at $16 Per Share on Nasdaq

Clinical-stage life sciences company Iambic Therapeutics (Nasdaq: IAM) priced its IPO at $16.00 per share, offering 9,375,000 shares of common stock for expected gross proceeds of $150.0 million before fees, per Investing.com. Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares.
Trading is expected to begin October 15, 2026 on the Nasdaq Global Select Market, with the offering set to close October 16. J.P. Morgan, Jefferies, BofA Securities and Citigroup are underwriting the deal; the registration statement became effective October 14.

Published Oct 14Source: Investing.com ↗

BioLive Wire · AI-collected

Vanda Pharmaceuticals Stock Falls After Anxiety Drug Trial Fails

Vanda Pharmaceuticals' on-demand anxiety drug VQW-765 failed its Phase 3 trial (Study 3201), which tested 546 adults with social anxiety disorder against placebo, per Investing.com. The primary endpoint showed no statistically significant difference in stress levels between VQW-765 and placebo during a performance task for female participants (p=0.8899), and a key secondary endpoint for the combined male-female population also failed (p=0.6605), despite numerical stress reductions seen in an earlier Phase 2 trial.
Vanda said VQW-765 was safe and well-tolerated consistent with prior studies, but the drug's development program is now on hold pending further analysis of the full dataset. Shares fell 6.2% in after-hours trading.

Published Oct 14Source: Investing.com ↗

BioLive Wire · AI-collected

GSK Plans to Cut Up to 1,217 Jobs in Belgium, Report Says

GSK plans to eliminate up to 1,217 positions at its Belgium facilities, according to Belgian newspaper L'Echo cited by Investing.com. The company notified unions of the plan the same day the report was published.
The article does not specify the reason for the cuts or which specific business units or plants are affected, stating only that Belgian facilities broadly are impacted.

Published Oct 14Source: L'Echo ↗

BioLive Wire · AI-collected

Olympus Shares Hit 12-Week Low After FDA Warning Over Quality Systems

Olympus's Tokyo-listed shares (7733) fell 12.92% to 1,770 yen on Tuesday, their lowest level since July 24, after the company disclosed an FDA warning letter dated October 7, according to Investing.com; the Nikkei rose 0.9% the same day.
The FDA raised concerns over Olympus's quality management system and related procedures following inspections of US, Japanese, and European facilities in late 2025. The letter does not specify the exact violations or affected products.
Olympus said it will submit a detailed response within 15 business days and provide regular updates until the FDA deems corrective actions adequate. The company said no additional customer action is needed, products remain safe when used per instructions, and the letter does not restrict manufacturing, distribution, sales, or new 510(k) applications.

Published Oct 14Source: Investing.com ↗

BioLive Wire · AI-collected

Liquidia Stock Surges 40% on $380.7M Litigation Settlement With UTHR

Liquidia and United Therapeutics (UTHR) reached a global settlement resolving six pending lawsuits for a combined $380.7 million, with mutual releases and no admission of liability by either side, according to Investing.com. Liquidia's shares jumped about 40% in after-hours trading on the news.
Liquidia's net payment is $175 million due within 30 business days, plus two $72.7 million installments due before January 31 and April 30, 2027; a separate $60.3 million covers Treprostinil Injection antitrust claimants this month. The settlement follows a September 30 Delaware federal court ruling that Liquidia infringed UTHR's patent on inhaled treprostinil for PH-ILD, which Liquidia will not appeal.
Liquidia has filed a supplement to remove the PH-ILD indication from its YUTREPIA label. YUTREPIA will continue to be supplied to pulmonary arterial hypertension patients; preliminary unaudited Q3 2026 YUTREPIA net sales were $222.7 million, with $396.1 million in cash as of September 30.

Published Oct 13Source: Investing.com ↗

BioLive Wire · AI-collected

BioNTech Stock Falls After Cancer Trial Misses Key Endpoint

BioNTech said a mid-to-late-stage trial of its experimental mRNA cancer therapy BNT113, combined with pembrolizumab as a first-line treatment for HPV-associated advanced head and neck cancer, failed to meet its first primary endpoint of improving progression-free survival compared with standard treatment alone, according to Investing.com. Nasdaq-listed BNTX shares fell 5% Tuesday following the announcement.
An independent data monitoring committee recommended the study continue to assess its second primary endpoint, overall survival; the trial will be considered a success if overall survival improves. BioNTech said it will not access ongoing data to avoid bias.

Published Oct 13Source: Investing.com ↗

BioLive Wire · AI-collected

Syndax Pharmaceuticals Stock Tumbles on Failed IPF Trial

Syndax Pharmaceuticals (Nasdaq: SNDX) said its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet its primary endpoint of annualized decline in forced vital capacity (FVC), and the company will not pursue further development in the IPF indication.
The trial enrolled 145 patients across 62 sites in 14 countries, randomized 2:1 to axatilimab 0.3 mg/kg or placebo every two weeks for 26 weeks. Safety was comparable to placebo with no new safety signals and no treatment-related deaths in either arm. Shares fell roughly 15% in after-hours trading Monday.
Syndax said the result does not affect ongoing trials in other indications, including chronic graft-versus-host disease (cGVHD), where axatilimab is already FDA-approved; data from those trials are expected later this year and in early 2028.

Published Oct 12Source: Investing.com ↗

NLP · 3-line summary

AI Articles & Report Summaries

Expert articles and reports as a 3-line summary + takeaway

All Industrials Big Tech Macro Financials Consumer Energy Bio Semis Battery

BioLive Wire · AI-collected

Arcus Biosciences Shares Fall 6% After Unveiling Casdatifan Kidney-Cancer Trial Data

Arcus Biosciences presented new clinical data at a New York investor event for its HIF-2alpha inhibitor casdatifan in clear cell renal cell carcinoma from its ARC-20 platform study, evaluating first-line combination therapy, second-line treatment, and later-line monotherapy; shares fell 6% following the presentation.
In first-line therapy (casdatifan plus zimberelimab, 30 patients, median follow-up 11.5 months), 6- and 12-month progression-free survival rates were 86% and 69%, with a confirmed objective response rate of 50%; in second-line therapy (casdatifan plus cabozantinib, 43 patients), median progression-free survival was 14.5 months. In the pooled previously treated monotherapy cohort, median overall survival was 35 months, median progression-free survival 13 months, and confirmed objective response rate 36%, with no unexpected safety signals observed as of the September 4, 2026 data cutoff.
The company said first-line progression-free survival exceeded benchmarks for pembrolizumab monotherapy and ipilimumab-plus-nivolumab combination therapy, and second-line results exceeded the cabozantinib-monotherapy benchmark; Phase 3 PEAK-20 (casdatifan plus ipilimumab/nivolumab) is set to begin later this year, and Phase 3 PEAK-1 (casdatifan plus cabozantinib, second-line) is ongoing.

Published 4d agoSource: Investing.com ↗

BioLive Wire · AI-collected

Alvotech Shares Jump Premarket After FDA Approves New Manufacturing Process for Simlandi

Biosimilar maker Alvotech said the FDA approved a new manufacturing process, "Process 2.0," for producing the adalimumab (Humira biosimilar Simlandi) drug substance at its DSM2 facility in Reykjavik, Iceland; the company said the process more than doubles drug-substance output per batch without changing upstream production scale, and demonstrated comparability to the existing approved process with quality, safety, and efficacy maintained.
Alvotech COO Joseph McClellan said "the new process allows us to manufacture the same quantity of drug substance in fewer batches," freeing up capacity that can be redirected to other products in the company's portfolio, which includes five approved biosimilars sold in multiple countries: Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva.
Shares rose more than 6% in premarket trading Tuesday; the approval follows a recent FDA capacity approval and gives the company more flexibility to respond to demand increases.

Published 4d agoSource: Investing.com ↗

BioLive Wire · AI-collected

AstraZeneca Partners With Oracle on AI-Driven Clinical Research

AstraZeneca and Oracle announced a partnership to use AI to improve clinical research processes, drawing on Oracle's AI, cloud computing, and data-management systems; the collaboration focuses on applying AI to connect scientific research with clinical workflows rather than discovering new drug targets.
Planned applications include clinical-trial patient recruitment, earlier disease diagnosis, and drug-safety monitoring; the first program will address hypertension treatment and clinical research in Abu Dhabi alongside healthcare group M42, before expanding to additional projects across the US, Middle East, and Europe.
The partnership is expected to span AstraZeneca's core therapeutic areas, including oncology, cardiovascular disease, kidney and metabolic disease, respiratory and immunology, and rare diseases; neither company disclosed financial terms or a contract duration.

Published 4d agoSource: Investing.com ↗

BioLive Wire · AI-collected

California Settles 23andMe Data Breach Claims for $6 Million

California Attorney General Rob Bonta's office said Monday the state will receive $6 million from bankrupt 23andMe to resolve state legal claims tied to the company's 2023 data breach, which exposed the genetic and other personal information of 6.9 million customers, including more than 855,000 California residents; the state alleged violations of California's Genetic Information Privacy Act, arguing consumers had not explicitly consented to the asset sale.
23andMe filed for bankruptcy in March 2025 amid falling demand and legal fallout from the breach, selling its business through auction for $305 million to TTAM Research Institute, a nonprofit controlled by co-founder Anne Wojcicki; separately, 23andMe agreed in bankruptcy proceedings to pay $46.75 million to victims of the 2023 breach.
The bankruptcy court had rejected California's objection to the sale and barred the state from suing the successor company; after losing an appeal in federal district court, California agreed to drop further appeals as part of the settlement. Bonta emphasized that consumers can still delete their genetic information.

Published 5d agoSource: Reuters ↗

BioLive Wire · AI-collected

Evaxion Stock Surges on 3-Year Melanoma Vaccine Trial Data

Evaxion said all patients in a Phase 2 trial of its AI-designed personalized cancer vaccine EVX-01 for advanced melanoma maintained the clinical response seen at year two through the three-year follow-up mark, with no tumor progression observed; patients received EVX-01 as monotherapy in year three.
At the two-year mark (presented at ESMO 2025), the trial showed a 75% objective response rate, 25% complete response, 92% durability of response, and no relapses after combining EVX-01 with Merck's Keytruda for the first two years; 6 of 12 responders entered a one-year extension on monotherapy. Additional two-year data showed 54% of patients had deepening responses after treatment, tumor shrinkage in 15 of 16 enrolled patients, and vaccine-specific T-cell responses against 86% of targeted neoantigens.
Evaxion shares (EVAX) rose 21.6% Monday; the company plans to present the data at the ESMO Congress 2026 in Madrid (October 23-27) followed by a webinar on October 29.

Published 5d agoSource: Investing.com ↗

BioLive Wire · AI-collected

Metis TechBio Inks Up to $1.1 Billion Deal With Eli Lilly for Drug Delivery Tech

Hong Kong-listed Metis TechBio signed a collaboration agreement with Eli Lilly for research and development of tissue-specific drug delivery technologies, with a total deal value of up to $1.1 billion; the article did not specify upfront payment, milestone terms, or payment structure, only the aggregate cap.
No specific timeline or further details on the collaboration's duration were given in the article.

Published 5d agoSource: Investing.com ↗

BioLive Wire · AI-collected

Medicalgorithmics Shares Rally on $67 Million Takeover Letter of Intent

Polish healthcare company Medicalgorithmics (MDG) said a Nasdaq-listed US healthcare company signed a letter of intent to acquire 100% of its shares for total consideration of at least $67 million, to be paid primarily in the acquirer's common stock.
The acquirer plans to raise at least 10 million euros in non-debt equity financing before or at the signing of a definitive agreement; the current stage is the letter of intent, with a final agreement still to follow and no timeline or closing conditions specified.
Medicalgorithmics shares jumped 7.4% following the announcement.

Published 5d agoSource: Investing.com ↗

BioLive Wire · AI-collected

GSK's Ris-Rez Shows 61% Response Rate in Small Cell Lung Cancer Trial

GSK said Monday its experimental lung-cancer drug risvutatug rezetecan (Ris-Rez), licensed from China's Hansoh Pharma, showed a confirmed response in 11 of 18 evaluable patients (about 61%) at the high 8 mg/kg dose in an early global trial of extensive-stage small cell lung cancer patients who had relapsed after prior treatment, versus 7 of 22 (32%) at the lower 6 mg/kg dose; Grade 3-or-higher adverse events were more frequent at the high dose (42%) than the low dose (15%).
The trial enrolled 50 patients, most previously treated with two prior therapies, with roughly 100.5 days of follow-up and enrollment still ongoing; standard-of-care median overall survival for this setting is about 12-13 months, though the article did not give a direct standard-of-care response-rate comparison. GSK said longer follow-up is needed to assess durability of response, and results will be presented at the ESMO Congress 2026 in Madrid.
GSK will advance the 8 mg/kg dose into its global late-stage trial EMBOLD SCLC-301, a decision informed by this data and by Hansoh's pivotal China trial, which GSK said showed a statistically significant overall-survival improvement; GSK holds exclusive global rights to the drug excluding mainland China, Hong Kong, Macau, and Taiwan, and more than 1,000 patients have received it across trials including a late-stage study in hormone-resistant prostate cancer.

Published 5d agoSource: Investing.com ↗

BioLive Wire · AI-collected

Novavax Shareholder Shah Capital to Step Back From Activist Role

Shah Capital said Friday it no longer seeks to influence control of Novavax, as the firm restructures its investment organization into a family office; Shah Capital filed to voluntarily withdraw its SEC registration as an investment adviser, with the newly formed Himanshu Shah Family Office LLC to manage investments going forward.
Shah Capital's beneficial holding stands at 10.54 million shares (about 6.39%), while founder, CEO/CIO Himanshu Shah's personal beneficial holding is 10.66 million shares (about 6.46%); per LSEG data, Shah is Novavax's second-largest shareholder.
A recent filing showed Shah Capital Fund LLC sold 2.8 million shares at an average price of about $11.35 on October 5. The article did not provide further detail on the reason for the activist withdrawal beyond the shift to a family office.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

Novartis Ends Mid-Stage Trial for Fabhalta in Lupus Nephritis

Novartis halted a mid-stage trial testing Fabhalta in patients with lupus nephritis, according to the US federal clinical-trials registry, updated October 15. The company cited 'strategic considerations' for the decision, made after completing Part 1; the registry listing did not provide further explanation, and did not indicate whether safety or efficacy concerns influenced the decision.
The trial was evaluating whether the oral drug, used alongside standard treatment, was safe and effective for lupus nephritis — severe kidney inflammation caused by the autoimmune disease lupus.
Fabhalta was first approved by the FDA in 2023 for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, and has since been approved for two kidney diseases, IgA nephropathy and C3 glomerulopathy; the article did not address whether this trial halt affects those approved indications.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

Eli Lilly's Weight-Loss Pill Foundayo Wins EU Drug Regulator's Backing

Eli Lilly's oral weight-loss pill Foundayo (orforglipron) received a recommendation for approval from an EMA committee, for use in adult weight management and type 2 diabetes treatment; final marketing authorization rests with the European Commission. It becomes the second oral weight-loss drug to win EU backing, after Novo Nordisk's oral Wegovy.
Bernstein analyst Courtney Breen expects a European launch for the obesity indication around year-end, while the diabetes indication's timing may vary by country based on individual reimbursement decisions. Foundayo launched in the US in April and the UK in August, posting $98 million in Q2 sales; oral Wegovy, which won EU approval in July and is also sold in the US, UK, and UAE, posted DKK 322 million (about $48.45 million) in the same period.
Context: Foundayo's US rollout has been slower than Wegovy's, which entered the market first, though Foundayo can be taken at any time of day without food or water restrictions — a differentiator whose effect on adoption remains unclear. Lilly has filed for approval in more than 40 countries; Lilly and Novo are both competing to expand access to oral obesity drugs, in a market expected to exceed $100 billion by 2030, with oral drugs seen as potentially broadening the obesity-treatment market by attracting patients who are averse to injections.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

City Therapeutics Allocated No Shares to Half of IPO Orders, Report Says

City Therapeutics allocated no shares to half of investor orders in its IPO, Bloomberg reported (via Investing.com) October 16. Demand from mutual funds and healthcare-specialist investors for the upsized offering reached several times the available share count; the top 5 investors received 65% of the allocation and the top 10 received about 90%, with company management reported to have been deeply involved in the allocation process. The article did not give a specific reason for excluding half of the orders beyond demand far exceeding supply.
As previously reported, the IPO priced 11,111,111 shares at $18.00 each, expected to raise about $200 million before fees, with underwriters holding a 30-day option for up to 1,666,666 additional shares; underwriters were Goldman Sachs, Jefferies, Stifel, and Oppenheimer. Shares were set to begin trading on the Nasdaq Global Market under ticker CTY.

Published Oct 16Source: Bloomberg ↗

BioLive Wire · AI-collected

Alector Stock Surges 13% on Premium-Priced Equity Offering

Alector shares jumped about 13% in Friday premarket trading after the company priced a registered direct offering of 36.6 million common shares at $2.05 per share — about a 7.3% premium to its October 15 closing price; the deal is expected to raise approximately $75.03 million before fees, with closing expected around October 19 subject to customary conditions.
New and existing investors are participating, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. Morgan Stanley and BTIG are acting as joint lead underwriters.
Alector, headquartered in South San Francisco, develops therapies aimed at slowing progression of neurodegenerative diseases. Proceeds are earmarked for R&D, manufacturing of drug candidates, working capital, capital expenditures, and general corporate purposes, as well as potential acquisitions or strategic transactions involving complementary products, technologies, or businesses. The article attributed the share-price jump to the above-prior-close offering pricing but did not provide further analysis of the market reaction.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

Omeros Shares Slide Following European Regulatory Setback for Narsoplimab

The European Medicines Agency's CHMP maintained a negative opinion on narsoplimab after re-examination, declining to approve it for transplant-associated thrombotic microangiopathy (TA-TMA) following stem-cell transplant — reaffirming its initial negative stance from June 2026. An 8-member expert group convened by CHMP had recommended that individual patient-level data be reviewed by outside experts, but per the report, CHMP did not provide that data to the expert group before its decision; Omeros had submitted substantial patient data in August.
Omeros shares fell about 4% in Friday morning trading. In response, Omeros told CHMP it will end its European compassionate-use program for the drug, citing surging US demand; European patients currently on the program will receive enough supply to complete their treatment course. The company plans to start trials for acute respiratory distress syndrome (ARDS) and prevention of high-risk pediatric TA-TMA later this year.
Narsoplimab targets MASP-2, an enzyme in the lectin pathway of the complement system. The FDA approved it in December 2025 under the brand name Yartemlea, the first FDA-approved treatment for TA-TMA in patients age 2 and older — a contrast the article drew with the EU rejection. The article noted it is the only marketed systemic complement inhibitor without a boxed warning, REMS, or specific vaccination requirements, and cited rising US demand as the direct reason for ending the European program.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

City Therapeutics Prices IPO at $18 Per Share, Raising $200 Million

City Therapeutics (ticker: CTY), a clinical-stage biotech developing RNA-interference therapies, priced its IPO at $18 per share for 11,111,111 shares, raising about $200 million before fees; the offering is entirely newly issued shares, with underwriters granted a 30-day option to purchase up to 1,666,666 additional shares. The stock lists on the Nasdaq Global Market, with the SEC registration statement effective October 15, trading starting October 16, and closing expected October 19.
Underwriters include Goldman Sachs & Co. LLC, Jefferies, Stifel, and Oppenheimer & Co. Key pipeline programs cited: CITY-FXI for thromboembolic disorders, CITY-RBP4 for Stargardt disease and other retinal disorders, and CITY-TFR2 for anemia related to chronic disease.
The article did not specify planned use of proceeds.

Published Oct 16Source: Investing.com ↗

BioLive Wire · AI-collected

Catalio Capital Seeks $500 Million for AI-Healthcare Startups, Bloomberg Reports

Catalio Capital is seeking $500 million for its second AI-healthcare-startup fund, named Nexus V, moved up from a previously planned 2027 launch, according to an investor letter cited by Bloomberg. Five existing portfolio companies will carry over into the new fund, including Doctronic (AI personalized healthcare) and Basecamp Research (AI-designed therapeutics).
Catalio's prior fund closed in July 2025 at over $400 million, with about 40% of its portfolio AI-related. The firm has sold three portfolio companies this year for a combined deal value exceeding $8 billion, and has taken seven companies public, including this week's $150 million Iambic Therapeutics IPO and June's $745 million Parabilis Medicines IPO.
KKR took a minority stake in Catalio in 2023, and KKR co-founder Henry Kravis chairs Catalio's board.

Published Oct 15Source: Investing.com ↗

BioLive Wire · AI-collected

Pennsylvania Secures $4 Billion in Investments, Governor Says

Pennsylvania Governor Josh Shapiro announced over $4 billion in life-sciences and private-sector investment commitments secured over the past week, per Investing.com. Merck committed $2.9 billion to expand its Montgomery County site through the end of 2030, including $550 million for a robotics- and AI-enabled drug R&D and manufacturing facility; GSK committed more than $800 million to expand its Upper Merion site for biopharmaceutical manufacturing and research, creating more than 300 jobs over five years.
The state also committed $371.5 million toward port infrastructure to expand container and vehicle handling capacity, expected to draw an additional $200 million in private investment and $266 million in federal support. The combined investments are expected to create more than 6,300 jobs for Pennsylvania residents.

Published Oct 15Source: Investing.com ↗

BioLive Wire · AI-collected

Iambic Therapeutics Prices IPO at $16 Per Share on Nasdaq

Clinical-stage life sciences company Iambic Therapeutics (Nasdaq: IAM) priced its IPO at $16.00 per share, offering 9,375,000 shares of common stock for expected gross proceeds of $150.0 million before fees, per Investing.com. Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares.
Trading is expected to begin October 15, 2026 on the Nasdaq Global Select Market, with the offering set to close October 16. J.P. Morgan, Jefferies, BofA Securities and Citigroup are underwriting the deal; the registration statement became effective October 14.

Published Oct 14Source: Investing.com ↗

BioLive Wire · AI-collected

Vanda Pharmaceuticals Stock Falls After Anxiety Drug Trial Fails

Vanda Pharmaceuticals' on-demand anxiety drug VQW-765 failed its Phase 3 trial (Study 3201), which tested 546 adults with social anxiety disorder against placebo, per Investing.com. The primary endpoint showed no statistically significant difference in stress levels between VQW-765 and placebo during a performance task for female participants (p=0.8899), and a key secondary endpoint for the combined male-female population also failed (p=0.6605), despite numerical stress reductions seen in an earlier Phase 2 trial.
Vanda said VQW-765 was safe and well-tolerated consistent with prior studies, but the drug's development program is now on hold pending further analysis of the full dataset. Shares fell 6.2% in after-hours trading.

Published Oct 14Source: Investing.com ↗

BioLive Wire · AI-collected

GSK Plans to Cut Up to 1,217 Jobs in Belgium, Report Says

GSK plans to eliminate up to 1,217 positions at its Belgium facilities, according to Belgian newspaper L'Echo cited by Investing.com. The company notified unions of the plan the same day the report was published.
The article does not specify the reason for the cuts or which specific business units or plants are affected, stating only that Belgian facilities broadly are impacted.

Published Oct 14Source: L'Echo ↗

BioLive Wire · AI-collected

Olympus Shares Hit 12-Week Low After FDA Warning Over Quality Systems

Olympus's Tokyo-listed shares (7733) fell 12.92% to 1,770 yen on Tuesday, their lowest level since July 24, after the company disclosed an FDA warning letter dated October 7, according to Investing.com; the Nikkei rose 0.9% the same day.
The FDA raised concerns over Olympus's quality management system and related procedures following inspections of US, Japanese, and European facilities in late 2025. The letter does not specify the exact violations or affected products.
Olympus said it will submit a detailed response within 15 business days and provide regular updates until the FDA deems corrective actions adequate. The company said no additional customer action is needed, products remain safe when used per instructions, and the letter does not restrict manufacturing, distribution, sales, or new 510(k) applications.

Published Oct 14Source: Investing.com ↗

BioLive Wire · AI-collected

Liquidia Stock Surges 40% on $380.7M Litigation Settlement With UTHR

Liquidia and United Therapeutics (UTHR) reached a global settlement resolving six pending lawsuits for a combined $380.7 million, with mutual releases and no admission of liability by either side, according to Investing.com. Liquidia's shares jumped about 40% in after-hours trading on the news.
Liquidia's net payment is $175 million due within 30 business days, plus two $72.7 million installments due before January 31 and April 30, 2027; a separate $60.3 million covers Treprostinil Injection antitrust claimants this month. The settlement follows a September 30 Delaware federal court ruling that Liquidia infringed UTHR's patent on inhaled treprostinil for PH-ILD, which Liquidia will not appeal.
Liquidia has filed a supplement to remove the PH-ILD indication from its YUTREPIA label. YUTREPIA will continue to be supplied to pulmonary arterial hypertension patients; preliminary unaudited Q3 2026 YUTREPIA net sales were $222.7 million, with $396.1 million in cash as of September 30.

Published Oct 13Source: Investing.com ↗

BioLive Wire · AI-collected

BioNTech Stock Falls After Cancer Trial Misses Key Endpoint

BioNTech said a mid-to-late-stage trial of its experimental mRNA cancer therapy BNT113, combined with pembrolizumab as a first-line treatment for HPV-associated advanced head and neck cancer, failed to meet its first primary endpoint of improving progression-free survival compared with standard treatment alone, according to Investing.com. Nasdaq-listed BNTX shares fell 5% Tuesday following the announcement.
An independent data monitoring committee recommended the study continue to assess its second primary endpoint, overall survival; the trial will be considered a success if overall survival improves. BioNTech said it will not access ongoing data to avoid bias.

Published Oct 13Source: Investing.com ↗

BioLive Wire · AI-collected

Syndax Pharmaceuticals Stock Tumbles on Failed IPF Trial

Syndax Pharmaceuticals (Nasdaq: SNDX) said its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet its primary endpoint of annualized decline in forced vital capacity (FVC), and the company will not pursue further development in the IPF indication.
The trial enrolled 145 patients across 62 sites in 14 countries, randomized 2:1 to axatilimab 0.3 mg/kg or placebo every two weeks for 26 weeks. Safety was comparable to placebo with no new safety signals and no treatment-related deaths in either arm. Shares fell roughly 15% in after-hours trading Monday.
Syndax said the result does not affect ongoing trials in other indications, including chronic graft-versus-host disease (cGVHD), where axatilimab is already FDA-approved; data from those trials are expected later this year and in early 2028.

Published Oct 12Source: Investing.com ↗